Abstract
Ideally, for the decision about the duration of vitamin K antagonists as secondary prophylaxis after an episode of venous thromboembolism, knowledge about at least three aspects is needed. First, the chance of a recurrence of venous thromboembolism, second, the risk of major bleeding complications, and third, the patient’s appreciation of being on or off warfarin. At present, the lack of solid data for most of these elements leaves the clinician with many uncertainties.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
